2016.6 – 现在      中国科学院上海有机化学研究所生物与化学交叉研究中心 研究员

2015.4 – 2016.5    哈佛医学院达纳法伯癌症研究所癌症生物学系  研究科学家

2010.4 – 2015.3  　哈佛医学院达纳法伯癌症研究所癌症生物学系，哈佛医学院生物化学与分子药学系  博士后

2009.7 - 2009.12    中国科学院上海有机化学研究所  助理研究员 

2004.9 - 2009.7     中国科学院上海有机化学研究所  有机化学博士

2000.9 - 2004.7     南京大学  化学学士

谭立课题组以潜在靶标蛋白结构及功能为导向，研发新颖、高特异性、高活性的小分子调节剂。

以自行研发的新型调节剂作为信号通路探针，进一步研究其靶标蛋白在癌症、炎症或神经退行性疾病中的病理功能，及作为治疗靶点的潜力。

优化先导化合物，研发临床治疗的候选药物。课题组当前关注作为维持蛋白质稳态的重要组件的靶蛋白——E3连接酶和去泛素化酶及一些激酶靶点。 

罗氏创新化学奖（2008） 　

南京大学人民奖学金 （2002-2003）

1. Li Tan#, Jun Wang#, Junko Tanizaki#, Zhifeng Huang#, Amir R. Aref#, Maria Rusan, Su-Jie Zhu, Yiyun Zhang, Dalia Ercan, Rachel G. Liao, Marzia Capelletti, Wenjun Zhou, Wooyoung Hur, NamDoo Kim, Taebo Sim, Suzanne Gaudet, David A. Barbie, Jing-Ruey Joanna Yeh, Cai-Hong Yun, Peter S. Hammerman*, Moosa Mohammadi*, Pasi A. J?nne*, and Nathanael S. Gray*, Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors, Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(45):E4869-4877.

2. Li Tan#, Koshi Akahane#, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, and Nathanael S. Gray*, Development of Selective Covalent Janus Kinase 3 Inhibitors, Journal of Medicinal Chemistry, 2015, 58(16):6589-6606.

3. Li Tan#, Tyzoon Nomanbhoy, Deepak Gurbani, Matthew Patricelli, John Hunter, Jiefei Geng, Lina Herhaus, Jianming Zhang, Eduardo Pauls, Youngjin Ham, Hwan Geun Choi, Ting Xie, Xianming Deng, Sara J. Buhrlage, Taebo Sim, Philip Cohen, Gopal Sapkota, Kenneth D. Westover, and Nathanael S. Gray*, Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2), Journal of Medicinal Chemistry, 2015, 58(1):183-196.

4. Hideki Terai#, Li Tan#, Ellen M. Beauchamp, John M. Hatcher, Qingsong Liu, Matthew Meyerson, Nathanael S. Gray,* and Peter S. Hammerman*, Characterization of DDR2 inhibitors for the treatment of DDR2 mutated non-small cell lung cancer, ACS Chemical Biology, 2015, 10(12):2687–2696.

5. Zhifeng Huang#, Li Tan#, Huiyan Wang#, Yang Liu, Steven Blais, Jingjing Deng, Thomas A. Neubert, Nathanael S. Gray, Xiaokun Li,* and Moosa Mohammadi*, DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors, ACS Chemical Biology, 2015, 10(1):299-309.

6. Hyung-Gu Kim#, Li Tan#, Ellen L. Weisberg#, Feiyang Liu#, Peter Canning#, Hwan Geun Choi#, Scott A. Ezell, Hong Wu, Zheng Zhao, Jinhua Wang, Anna Mandinova, James D. Griffin, Alex N. Bullock, Qingsong Liu,* Sam W. Lee,* and Nathanael S. Gray*, Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor, ACS Chemical Biology, 2013, 8(10):2145-2150.

7. Li Tan#, Deepak Gurbani#, Ellen L. Weisberg, John C. Hunter, Lianbo Li, Douglas S. Jones, Scott B. Ficarro, Samar Mowafy, Chun-Pong Tam, Suman Rao, Guangyan Du, James D. Griffin, Peter K. Sorger, Jarrod A. Marto, Kenneth D. Westover*, Nathanael S. Gray*, Structure-guided development of covalent TAK1 inhibitors, Bioorganic & Medicinal Chemistry, 2017, 25(3):838-846.

8. Li Tan#, Deepak Gurbani#, Ellen L. Weisberg#, Douglas S. Jones#, Suman Rao, William D. Singer, Faviola M. Bernard, Samar Mowafy, Annie Jenney, Guangyan Du, Atsushi Nonami, James D. Griffin, Douglas A. Lauffenburger, Kenneth D. Westover*, Peter K. Sorger*, Nathanael S. Gray*, Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors, Bioorganic & Medicinal Chemistry, 2017, 25(4):1320-1328.

9. Li Tan#, Dawei Ma*, Total synthesis of salinamide A: a potent anti-inflammatory bicyclic depsipeptide, Angewandte Chemie International Edition, 2008, 47(19):3614-3617.